HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Evaxion Biotech (NASDAQ:EVAX) and maintained a $14 price target.
April 03, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Evaxion Biotech with a $14 price target.
The reiteration of a Buy rating and maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards EVAX, potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100